Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

Mundipharma empowers global healthcare access with acquisition of Rezafungin rights

Mundipharma empowers global healthcare access with acquisition of Rezafungin rights
The acquisition by Mundipharma aims to intensifying focus on infectious diseases

In a recent announcement, Mundipharma, a leading global pharmaceutical company, has announced its acquisition of all assets and rights related to rezafungin from Cidara Therapeutics.

This solidified Mundipharma's dedication to managing infectious diseases and specialty care therapeutic areas, especially invasisve candidiasis which over the 15 years has seen no new therapeutic developments underscoring for alternative options.


The FDA and MHRA approved rezafungin is a groundbreaking once-weekly echinocandin antifungal drug specifically designed for the treatment of invasive candidiasis in adults.

While Mundipharma will oversee global commercialization efforts, Melinta Therapeutics will retain commercialization rights for rezafungin in the United States.

Moreover, the acquisition empowers the pharmaceutical company with global ownership of rezafungin, encompassing its ongoing development and distribution.

According to Marc Princen, Mundipharma's Chief Executive Officer, the strategic move positions the company to fully unleash the potential of rezafungin which has been granted Orphan Drug Designation in multiple regions, emphasizing its significance in addressing unmet medical needs.

"We are committed to ensuring patients affected with invasive candidiasis have access to an additional treatment option to manage this potentially life-threatening condition," Princen said.

Currently available to patients in the UK and Germany, Mundipharma aims to expedite further marketing authorizations to extend patient access.

The acquisition underscores Mundipharma's unwavering commitment to advancing therapeutic solutions for critical medical conditions, reaffirming its position as a frontrunner in the global healthcare landscape.

What is Invasive Candidiasis?

Invasive candidiasis a severe and potentially life-threatening infection of the bloodstream and/or deep tissues. This condition predominantly affects individuals with compromised immune systems, with mortality rates exceeding 40 per cent.

*Assets and rights acquired by Napp Pharmaceutical Group Limited, a member of the international network of Mundipharma independent associated companies.*

More For You

Community Pharmacy England (CPE) chief executive Janet Morrison was one of the signatories of the statement

Community Pharmacy England (CPE) chief executive Janet Morrison was one of the signatories of the statement

Primary care leaders join forces in effort to 'transform investment into primary care'

Community Pharmacy England (CPE) has teamed up with other national primary care bodies to urge the government to allocate more funds towards the sector.

In a joint statement released on the back of the government’s spending review, last week, the organisations welcomed the government’s continued determination to ‘shift care from hospitals to community and from sickness to prevention’ but warned that this would not be possible ‘without further investment in primary care’.

Keep ReadingShow less
Cancer patients warned against using weight-loss jabs

Macmillan Cancer Support said there is not enough evidence on how the weight-loss jabs might affect anti-cancer treatments.

iStock

Cancer patients warned against using weight-loss jabs

Cancer patients have been advised to consult their doctor before taking any weight-loss jabs.

Macmillan Cancer Support has issued this advisory following a surge in calls by cancer patients asking whether they can take fat loss jabs such as Wegovy and Mounjaro.

Keep ReadingShow less
Kamson Pharmacy to deliver more clinical services after installing hub and spoke technology

The FLOWRx auto hub in the new Kamson warehouse in Uckfield.

Kamson Pharmacy to deliver more clinical services after installing hub and spoke technology


Kamsons Pharmacy has announced that it has implemented a state-of-the-art hub and spoke dispensing model with the aim of freeing up more time to deliver clinical services.

Keep ReadingShow less
RPS group aims to tackle barriers holding back black pharmacy students

Work is underway to improve inclusivity in teaching

Pic credit: iStock

RPS group aims to tackle barriers holding back black pharmacy students

A cross-sector group aimed at tackling barriers that block the progression of black students and trainee pharmacists held its first meeting this week.

The Royal Pharmaceutical Society (RPS) has created the Differential Attainment Oversight Group to address issues that black or black British African student pharmacists and foundation trainees face such as limited access to work experience, financial support and visible role models in education and training.

Keep ReadingShow less
Older adult organizing medicine bottles in a cool, dry storage area during warm weather.

People are being advised to keep medicine below 25° C

Pic credit: iStock

Pharmacies advise patients on storing medicines safely during heatwave

Patients are being given important advice and guidance on the impact heat can have on their medicine and where to keep different medicines as the UK goes through a heatwave.

People are being advised to keep medicine below 25° C if they are able to, unless storage instructions state it needs to be kept at an alternative temperature, such as drugs that need to be refrigerated.

Keep ReadingShow less